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Abstract
Introduction
Blacks have the highest incidence of and death from pros-
tate cancer in the United States. Screening with prostate-
specific antigen (PSA) may decrease mortality. Repeated 
testing allows for the calculation of PSA velocity (change 
of PSA over time), which may be a more clinically useful 
test for prostate cancer than a single PSA measurement. 
The objective of this study was to examine whether blacks 
were as likely as whites to report having had repeated 
PSA testing.
Methods
The Maryland Cancer Survey 2006 was a population-
based, random-digit−dialed statewide survey on cancer 
screening and risk behaviors of adults aged 40 years or 
older. We analyzed self-reported information on repeated 
PSA testing (2 PSA tests in the preceding 3 years) for 
1,721 black and white men. We used logistic regression to 
estimate the effect of race and age on repeated PSA test-
ing, adjusting for other covariates.
Results
Sixty-five percent of men reported ever having had a PSA 
test; 41% had repeated PSA testing in the past 3 years. 
Blacks aged 40 to 49 were more likely to report hav-
ing repeated PSA testing than whites in this age group 
(adjusted odds ratio [AOR], 3.3; 95% confidence interval 
[CI], 1.6-6.5). Blacks aged 60 to 69 were less likely to 
report repeated PSA testing than whites (AOR, 0.4, 95% 
CI, 0.2-0.8). No difference was seen by race among men 
aged 50 to 59 and men aged 70 or older. Repeated PSA 
testing was associated with living in an urban area and 
with having higher education, health insurance, a family 
history of prostate cancer, and having discussed cancer 
screening with adoctor.
Conclusions
Self-reported repeated PSA testing differed by age and 
race, being higher among blacks aged 40 to 49 and lower 
among blacks aged 60 to 69, compared with whites in their 
respective age groups. 
Introduction
Excluding skin cancer, prostate cancer is the most fre-
quently diagnosed cancer in men in the United States 
and is the second leading cause of cancer death after lung 
cancer (1). In 2008, there were an estimated 186,000 new 
cases of prostate cancer and more than 28,000 deaths. 
From 2000 through 2004, the age-adjusted incidence was 
approximately 60% higher among black men compared 
with white men (256/100,000 vs 161/100,000). The age-
adjusted death rate was approximately 140% higher in 
blacks than whites for this same period (62/100,000 vs 
26/100,000) (2).
Two screening tests are commonly used to detect pros-
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tate cancer: digital rectal examination (DRE) and serum 
prostate-specific antigen (PSA). In 2006, recommenda-
tions from the American Cancer Society (ACS) suggested 
that prostate cancer screening with PSA and DRE be 
offered annually to men aged 50 and older who have 
a life expectancy of at least 10 years. Men at high risk 
(including blacks and men with a family history of pros-
tate cancer in 1 or more first-degree relatives diagnosed 
at an early age) should begin annual testing at age 45. 
Benefits and limitations of screening should be discussed 
so an informed decision about testing can be made (3). 
Interpretation of PSA concentration is difficult; there is 
no well-defined cutoff value for the diagnosis of cancer 
because of overlap in serum PSA levels in patients with 
benign disease and cancer (4). PSA level can increase 
with age and may be elevated in nonmalignant condi-
tions such as benign prostatic hyperplasia and prostatitis 
(5). Prostate cancer can be present even at low PSA con-
centrations (≤3 ng/mL) (6,7).
Two large clinical trials have reported conflicting results 
on the effectiveness of PSA testing in decreasing death. 
The European Randomized Study of Screening for Prostate 
Cancer found that PSA screening reduced the rate of 
death from prostate cancer by 20% (8). The Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial in 
the United States found no significant difference in death 
rates from prostate cancer in men who were screened with 
PSA and men who were not (9).
Previous studies have shown the prevalence of PSA test-
ing differs for whites and blacks. Gilligan et al examined 
Medicare and Medicaid claims data in New Jersey and 
concluded that elderly blacks were less likely to undergo 
PSA testing than were elderly whites (10). Fowke et al 
found differences in screening rates by race and age in 
a large sample of men attending community health cen-
ters in the southern United States; blacks younger than 
50 were more likely to have had a recent PSA test than 
whites of the same age group, but among men older than 
65, blacks were less likely to have had a recent PSA test 
(11). When examining a sample of men aged 40 to 49, 
Scales et al found that a higher proportion of black non-
Hispanic men reported having had a PSA test than white 
non-Hispanic men (12).
PSA velocity is defined as the rate of change of serum PSA 
over time. Observational studies suggest the PSA velocity 
may be a more clinically useful screening test for prostate 
cancer than a single PSA concentration (13-15). A high 
PSA velocity may be a marker of high-risk prostate cancer 
or of prostate cancer aggressiveness (16,17). In 2007, the 
National Comprehensive Cancer Network guidelines for 
prostate cancer detection suggested that men with a PSA 
velocity higher than 0.35 ng/mL/y should consider biopsy, 
even if their PSA concentration is low (18). To date, how-
ever, no randomized trials have been conducted to deter-
mine the clinical usefulness of PSA velocity for decreasing 
cancer deaths.
Although several studies have examined the effect of 
race on prevalence of self-reported PSA testing, few have 
examined the effect of race on repeated PSA testing. The 
objective of our study was to determine whether black men 
were as likely as whites to report having had 2 PSA tests 
within the preceding 3 years in Maryland.
Methods
Research design
We performed a secondary analysis of data collect-
ed from the 2006 Maryland Cancer Survey (MCS), a 
population-based, cross-sectional statewide telephone sur-
vey on cancer screening rates, behavioral risk factors 
related to cancer, and access to health care among adults 
aged 40 or older living in Maryland (19) (Appendix). The 
random-digit–dialed survey employed disproportionate 
stratified sampling. Maryland was divided into 2 geo-
graphic strata: urban (consisting of Baltimore City and the 
7 counties in the Metropolitan Baltimore-Washington, DC, 
area) and rural (consisting of the remaining 16 counties in 
western and southern Maryland and the Eastern Shore 
of Maryland). Genesys Marketing Systems Group (Fort 
Washington, Pennsylvania) provided a pool of 70,020 ran-
dom telephone numbers. The rural area was oversampled, 
making up 40% of the telephone number pool, whereas 
the rural population represented 21.5% of the Maryland 
population.
REDA International, Inc (Wheaton, Maryland) conducted 
the MCS 2006 by using computer-assisted telephone inter-
viewing technology. For each telephone number, 15 calling 
attempts were made. If someone answered the telephone, 
the number was confirmed to be a residential telephone 
number. (Cellular telephones and nonresidential numbers 
were excluded.) If REDA determined that at least 1 person 
aged 40 or older was living in the household, he or she 
was invited to participate in the survey. If 2 or more age-
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eligible people lived there, 1 was randomly selected to be 
interviewed. The anonymous survey lasted approximately 
20 minutes. Respondents who spoke only Spanish were 
interviewed in Spanish by a bilingual interviewer.
A total of 61,273 telephone numbers were screened or 
called. Of these, 8.5% (5,187 telephone numbers) resulted 
in completed interviews. Of the numbers called, some 
(29.6%) were nonworking numbers; 13.6% were telephone 
numbers of a business or institution; and 4.3% were 
dedicated fax/modem numbers. Approximately 0.4% of 
the numbers were ineligible because of a language barrier 
(ie, a language other than English Spanish was spoken). 
The remaining telephone numbers (43.6%) were ineli-
gible for various reasons. The Council of American Survey 
Research Organizations response rate was 39.7%. The 
completion rate, defined as completed interviews/known 
eligible, was 75.1%.
People excluded from participation included those younger 
than 40, those who were unable to communicate because 
of a physical or mental impairment, and those living in 
group homes or institutions. The study was conducted 
between January and July 2006 and was approved by the 
institutional review boards at the University of Maryland, 
Baltimore, and the Maryland Department of Health and 
Mental Hygiene.
Definition of variables
The study variable, race, was self-reported as white or 
black/African American. (Because of the small number of 
Hispanics who responded to the survey (n = 117), Hispanic 
ethnicity was not included as a separate race/ethnicity 
category.) The outcome variable, repeated PSA testing, 
was defined as a report of having had 2 PSA tests in the 
preceding 3 years. After a description of the PSA test was 
read, the following questions were asked: “Have you ever 
had a PSA test?” “How long has it been since you had your 
last PSA test?” and “How long before that PSA test was 
the previous one?” Respondents who reported having had 
2 PSA tests within the previous 3 years were considered 
to have repeated PSA testing. Respondents who had never 
been tested, who reported having had only 1 PSA test, or 
who had had 2 PSA tests within a time frame longer than 
3 years or within an unknown time interval were consid-
ered not to have had recent repeated testing. The first 2 
questions are derived from the Behavioral Risk Factor 
Surveillance System survey (www.cdc.gov/brfss/question-
naires/english.htm), and the third is from the 2003 Health 
Information National Trends Survey (hints.cancer.gov/
questions/section1.jsp?section=Prostate+Cancer).
We included the following covariates in the analysis: area 
of residence (urban or rural), age in years (40-49, 50-59, 60-
69, ≥70), education (high school graduate or less compared 
with some college or more), health status (excellent, very 
good, or good compared with fair or poor), having health 
insurance, having a family history of prostate cancer, and 
having a discussion about prostate cancer screening with 
a health care professional.
A total of 5,187 people were interviewed for the survey. We 
excluded people who did not report race (n = 38), women 
(n = 3,235), men whose race was not white or black (n = 
72), and men who did not respond to the PSA question (n 
= 121), leaving 1,721 respondents for analysis.
Statistical methods
Frequencies by race and repeat PSA tests were determined 
for all covariates; the χ2 statistic was used to evaluate the 
association between the outcome variable and covariates. 
The following characteristics were included in the logistic 
regression model: race, age, area of residence, education, 
health insurance, family history of prostate cancer, and 
discussion of prostate cancer with a health care profes-
sional. Data were analyzed with SAS version 9.1 (SAS 
Institute, Inc, Cary, North Carolina).
Results
Compared with black respondents, whites were signifi-
cantly more likely to report a high educational level, hav-
ing some type of health insurance, and having discussed 
prostate cancer screening with a health care professional 
(Table 1). There was no difference in reporting a family 
history of prostate cancer by race. A higher proportion of 
white respondents reported having had repeated testing 
in the preceding 3 years. The unadjusted odds of repeated 
PSA testing were significantly higher in whites com-
pared with blacks (unadjusted odds ratio [OR], 1.5; 95% 
confidence interval [CI], 1.1-2.0; P value = .01; data not 
shown).
The reported prevalence of repeated PSA testing varied 
by race and age (Table 2). Within race, repeated testing 
increased with advancing age among both blacks and 
whites. The prevalence of repeated testing by race varied 
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by age group. A higher proportion of blacks than whites 
aged 40 to 49 reported repeated PSA testing; this was 
reversed in the group aged 60 to 69, in which fewer blacks 
than whites reported repeated PSA testing. The associa-
tion between race and repeated PSA testing differed by 
age. After adjusting for other covariates, black men aged 
40 to 49 had more than 3 times higher odds than white 
men of reporting repeated PSA testing. Blacks aged 60 to 
69 had lower odds of reporting repeated PSA testing than 
whites (adjusted OR, 0.4; 95% CI, 0.2-0.8). Black men aged 
70 or older were less likely to report repeated testing than 
white men, but the difference was not significant. No dif-
ference was seen by race for men aged 50 to 59.
We analyzed the adjusted association between repeated 
PSA testing and age, race, and other variables (Table 3). 
Comparing each race and age category to white men aged 
50 to 59 as the reference, white men aged 40 to 49 had the 
lowest odds of reporting repeated PSA testing, followed 
by black men in that age group. There was no difference 
between the reference group and black men aged 50 to 
59 and 60 to 69. Increased odds of repeated PSA testing 
were seen for white men aged 60 to 69 and 70 or older. 
Compared with the reference group, black men aged 70 or 
older had increased odds of repeated PSA testing but the 
finding was not significant. The odds ratios for the oldest 
white men (aged 60-69 and 70 or older) were higher than 
for black men of the same age groups. The odds of repeated 
PSA testing were higher among urban respondents, men 
with more than a high school education, men who had 
health insurance, and men who reported a family history 
of prostate cancer. The odds of having repeated PSA test-
ing were highest in men who reported having discussed 
prostate cancer screening with a health care professional.
Discussion
Our study found that repeated PSA testing differed by 
race and by age group. In the youngest age group (40-49 
y), blacks were more likely to report repeated PSA testing 
than whites, whereas among men 60 to 69, blacks were 
less likely to report repeated PSA testing than whites. 
Whites aged 60 to 69 and 70 or older had the highest odds 
of repeat PSA testing. 
Two studies were found examining the effect of race on 
repeated PSA testing. Mariotto et al used information 
from 2 data sources (2000 National Health Interview 
Survey and Medicare claims data) to model the distri-
bution of age at initial PSA testing and the distribution 
of inter-screening intervals to generate individual PSA 
screening histories that reflected the population screening 
(20). Their modeling arrived at results similar to those of 
our analysis; blacks in younger age groups and whites in 
older age groups were more likely to have had repeated 
PSA testing.
Ross et al used data from the 2000 National Health 
Interview Survey to examine responses to the question 
“How many PSA tests have you had in the last 5 years?” 
(21). In the adjusted analysis, there was no difference 
by race among men 50 or older. Although the number of 
men aged 40 to 49 was small, a somewhat higher propor-
tion of blacks than whites reported having had 3 tests in 
the last 5 years. As with our study, higher prevalence of 
repeated PSA testing was seen with higher educational 
levels and having health insurance. Although the ques-
tion that defined repeated PSA testing was different from 
that used in our survey, the results were similar; younger 
blacks reported a higher rate of repeated PSA testing than 
whites. Our analysis differed from that by Ross et al in 
that we examined men aged 50 or older in 3 age groups 
and had differing results for race by age as noted above. 
Although the finding was not significant, blacks aged 70 or 
older also reported lower prevalence of repeated PSA test-
ing. Prostate cancer screening is covered under Medicare 
Part B insurance. Men with only Medicare Part A (hospi-
tal insurance) may respond that they have health insur-
ance yet not have the test because of lack of insurance that 
covers PSA testing; these questions were not asked during 
our survey.
At the time of the survey in 2006, ACS recommended that 
black men be offered prostate cancer screening earlier 
than white men, beginning at age 45, because they are 
at increased risk to develop prostate cancer compared 
with whites. This may explain why black men aged 40 
to 49 were more likely to report repeated PSA testing. 
As has been shown previously, having a family history of 
prostate cancer yielded higher odds of reporting repeated 
PSA testing. Our analysis also showed that having a dis-
cussion about prostate cancer testing with a health care 
professional resulted in the highest odds of repeated PSA 
testing. This could be the result of recall bias: respon-
dents who had discussed the test with their doctor better 
remembered having had the test. Alternatively, men who 
discuss the risks and benefits of prostate cancer screening 
may choose to be screened, believing that any test for can-
cer is better than no test at all.
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As noted earlier, screening for prostate cancer with PSA is 
controversial. There is evidence that many of the cancers 
detected by PSA would not have otherwise been found, 
resulting in overdiagnosis (the diagnosis of cancer through 
screening that would not have been detected during the 
patient’s lifetime) (22) and aggressive treatment of low-
risk tumors (23). Today men with cancers at low risk for 
progression (Gleason score ≤6 and a clinical stage of T1c 
or T2a) are being offered a new treatment option, active 
surveillance, in which PSA tests and DREs are done more 
frequently (every 3-6 months) with prostate biopsies every 
12 to 24 months. The goal of this strategy is to spare men 
with low-risk cancers the possible side effects of aggressive 
treatment, including incontinence and sexual dysfunction 
(24).
Our study is subject to limitations that could influence 
the results. The sample excluded people who do not have 
landline telephones. If men without landline telephones 
(cellular telephones only or no telephone) are, for example, 
less likely to have health insurance or routine screening, 
then our survey may overestimate the prevalence of pros-
tate cancer testing. However, because the proportion of 
adults living in households with only cellular telephones 
decreases with increasing age, noncoverage bias based on 
telephone access probably introduces minimal bias into 
our study (25). The PSA test is a blood test and may be 
performed with other blood tests without the respondent’s 
knowledge, which may underestimate PSA screening 
rates. All data in the 2006 MCS are based on self-report, 
and reports were not validated by comparison to medical 
records. Self-report could lead to an underestimate or over-
estimate of screening prevalence. We did not ask the rea-
son why the initial or repeated PSA test was performed. 
Although most tests are done for cancer screening, the 
PSA test could also be drawn as follow-up to an already 
elevated PSA level, or after treatment for prostate cancer. 
The study also has several strengths. The data came from 
a large statewide sample, and we were able to adjust for 
several covariates. This survey was offered in Spanish to 
those who preferred to respond in that language to reach 
a larger portion of the Latino community. Our results 
showing differences in PSA screening may be generaliz-
able to other areas of the country because our sample was 
population-based.
Guidelines for prostate cancer screening have changed over 
time and vary by professional organization. Previously, 
ACS recommended that PSA tests and DREs be offered 
annually to men who had a life expectancy of at least 
10 years in a process of informed decision making (26). 
Guidelines stated that, if asked to make the decision 
for a patient, providers should have the patient tested. 
Currently, the ACS recommends that men discuss the 
pros and cons of prostate cancer screening with their 
health care provider. For men who wish to be tested, ACS 
has guidelines for testing based on age, risk history, and 
results of PSA testing (27). The US Preventive Services 
Task Force statement, updated in 2008, recommends that 
health care providers discuss the “potential but uncertain 
benefits and the known harms” of prostate cancer screen-
ing and treatment with their patients before screening 
(28). The American Urological Association has developed 
a recent best practices statement (2009) that screening 
should be individualized following discussions between 
the health care provider and the patient (29). In addition, 
they recommend that the discussion and possible screen-
ing begin at age 40 for all men with a life expectancy of 
10 years, to establish a baseline measurement with which 
future tests can be compared and PSA velocity can be 
determined. According to National Comprehensive Cancer 
Network guidelines, DRE and PSA testing are recom-
mended for patients at age 40 to determine a baseline 
value. The time interval between follow-up tests should be 
based on the patient’s initial PSA measurement, race, and 
family history of prostate cancer (30).
Although the guidelines for prostate cancer screening 
vary by organization, what is recommended by each is 
that men discuss the risks and benefits of screening with 
their health care providers and then make an informed 
decision before undertaking this testing. Once screening 
is begun, intervals for repeat screening should be based on 
PSA level, age, and family history. Our study found that a 
lower proportion of black men reported having had the dis-
cussion with their providers. We also found differences in 
repeated PSA testing by race and age, level of education, 
and health insurance status. If prostate cancer screening 
proves to be useful in the detection and management of 
prostate cancer, the disparities in screening need to be 
addressed and future studies need to be done to measure 
screening trends by race over time. In the meantime, the 
discussion about prostate cancer screening should become 
part of a routine medical visit for eligible men.
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Tables
Table 1. Baseline Characteristics of Male Respondents Aged 40 Years or Older Who Responded to Questions on Prostate Cancer 
Screening by Race, Maryland Cancer Survey, 2006
Characteristic
n (%)
P ValueaTotal (n = 1,721) White (n = 1,497) Black (n = 224) 
Area of residenceb
Urban 98 (5.) 80 (5.8) 181 (80.8)
<.001
Rural  (2.) 91 (.2)  (19.2)
Age, y
0-9 1 (2.) 8 (25.9) 8 (.5)
<.001
50-59 51 (0.0) 9 (0.0) 8 (0.)
0-9 8 (20.2) 10 (20.) 8 (1.0)
≥70 85 (22.) 51 (2.)  (15.2)
Education
High school graduate or less 55 (2.2) 2 (0.9) 92 (1.1)
.002
Some college or more 1,1 (.8) 1,05 (9.1) 12 (58.9)
Health statusc
Excellent to good 1,51 (8.8) 1,2 (85.5) 1 (80.1)
.0
Fair or poor 20 (15.2) 21 (1.5)  (19.9)
Has health insurance
Yes 1,2 (9.5) 1,21 (9.9) 205 (91.5)
.0
No 95 (5.5)  (5.1) 19 (8.5)
Family history of prostate cancerc
Yes 208 (12.) 180 (12.2) 28 (12.8)
.80
No 1,8 (8.) 1,295 (8.8) 191 (8.2)
Discussed prostate screening with a health care professionalc
Yes 1,10 (5.0) 98 (.2) 125 (5.8)
.00
No 59 (5.0) 99 (.8) 95 (.2)
Ever had PSA testing
Yes 1,115 (.8) 982 (5.) 1 (59.)
.0
No 0 (5.2) 515 (.) 91 (0.)
Had repeated PSA testingd
Yes 0 (0.9) 29 (2.0)  (.0)
.01
No 1,018 (59.1) 88 (58.0) 150 (.0)
 
Abbreviation: PSA, prostate-specific antigen. 
a Calculated by χ2 test. 
b Urban defined as Baltimore City and the  counties in the Metropolitan Baltimore-Washington, DC, area; rural defined as the remaining 1 counties in west-
ern and southern Maryland and the eastern shore of Maryland. 
c Some responses missing.  
d Report of having 2 PSA tests in the preceding  years.
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Table 2. Adjusteda Association of Repeated PSA Testingb in Blacks Compared With Whites, Stratified by Age, Maryland Cancer 
Survey, 2006
Age, y
Blacks Who Reported Repeated PSA 
Testing
Whites Who Reported Repeated PSA 
Testing
AORa (95% CI) P Valuen (%) P Value n (%) P Value
0-9 1 (20.2)
.001
2 (8.)
<.001
. (1.-.5) <.001
50-59 22 (2.) 19 (9.9) 1.0 (0.5-1.8) .98
0-9 1 (2.1) 192 (1.9) 0. (0.2-0.8) .01
≥70 19 (55.9) 22 (.) 0. (0.-1.5) .2
 
Abbreviations: PSA, prostate-specific antigen; AOR, adjusted odds ratio; CI, confidence interval. 
a Adjusted for area of residence, education level, health insurance, family history of prostate cancer, and having discussed prostate screening with a health 
care professional. 
b Report of having had 2 PSA tests in the preceding  years.
Table 3. Adjusted Association Between Repeated PSA Testinga and Different Predictors by Multiple Logistic Regression,b 2006 
Maryland Cancer Survey
Characteristic Odds Ratio (95% CI) P Value
Race and age groups
White
0-9 y 0.2 (0.1-0.) <.001
50-59 y 1 [Reference] NA
0-9 y 2. (1.9-.) <.001
≥70 y .0 (2.2-.1) <.001
Black
0-9 y 0. (0.-1.1) .09
50-59 y 1.0 (0.-1.9) .98
0-9 y 1.0 (0.5-2.0) .99
≥70 y 2.0 (0.9-.) .09
Area of residence
Urban 1. (1.0-1.)
.0
Rural 1 [Reference]
Education
Some college or more 1. (1.-2.2)
<.001
High school graduate or less 1 [Reference]
Characteristic Odds Ratio (95% CI) P Value
Health insurance
Yes .9 (1.-9.)
.00
No 1 [Reference]
Family history of prostate cancer
Yes 1. (1.1-2.)
.01
No 1 [Reference]
Discussed prostate cancer screening with a health care professional
Yes . (.5-.2)
<.001
No 1 [Reference]
 
Abbreviations: PSA, prostate-specific antigen; CI, confidence interval; NA, not 
applicable.  
a Report of having had 2 PSA tests in the preceding  years. 
b Adjusted for area of residence, education level, health insurance, family 
history of prostate cancer, and having discussed prostate screening with a 
health care professional.
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Appendix. Questions on Prostate Cancer 
Screening From the Maryland Cancer 
Survey, 2006 
A prostate-specific antigen test, also called a PSA test, is a blood test used 
to check men for prostate cancer. Have you ever heard of this test?
1 YES
2 NO
 DON’T KNOW/NOT SURE
8 REFUSED
9 NA
Have you ever had a PSA test?
1 YES
2 NO
 DON’T KNOW/NOT SURE
8 REFUSED
9 NA
How long has it been since you had your last PSA test?
(READ ONLY IF NECESSARY)
1 Within the past year (<12 MONTHS AGO)
2 Within the past 2 years (>1 YEAR BUT <2 YEARS AGO)
 Within the past  years (>2 YEARS BUT < YEARS AGO)
 Within the past 5 years (> YEARS BUT <5 YEARS AGO)
5 5 or more years ago
 Never
 DON’T KNOW/NOT SURE
8 REFUSED
9 NA
You said your last PSA test was [INSERT TIME FRAME]. How long before that 
PSA test was the previous one?
1 A year or less before
2 More than 1 but not more than 2 years before
 More than 2 but not more than 5 years before
 Over 5 years before
5 None before the most recent
 DON’T KNOW/NOT SURE
8 REFUSED
9 NA
